Pharmaceuticals announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin, an oral, non-opioid ...
If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback